Professor Mamello Sekhoacha is an Associate Professor of Pharmacology at the University of the Free State, and was previously a Specialist Scientist at the South African Medical Research Council, South Africa. She obtained her PhD in Pharmacology in 2008 from the University of Cape Town, South Africa. She holds a BSc degree in Biochemistry and an Honours degree in Pharmacology. She is a qualified Clinical Research Associate (CRA) and holds further qualifications in Ethics and Governance. Prof Sekhoacha has over 18 years’ experience in the Pharmacology research field of drug discovery for the treatment of various ailments including cancer, gangrene, malaria, and HIV. She is experienced in experimental laboratory research, research involving the use of animals, and clinical research. Her research addresses challenges of chemoresistance and chemotoxicity through the discovery of new lead compounds, identification of proteins and genes responsible for drug resistance and treatment failure, and development of targeted of chemotherapeutic nano-delivery systems.
Professor Mamello Sekhoacha is an Associate Professor of Pharmacology at the University of the Free State, and was previously a Specialist Scientist at the South African Medical Research Council, South Africa. She obtained her PhD in Pharmacology in 2008 from the University of Cape Town, South Africa. She holds a BSc degree in Biochemistry and an Honours degree in Pharmacology. She is a qualified Clinical Research Associate (CRA) and holds further qualifications in Ethics and Governance. Prof Sekhoacha has over 18 years’ experience in the Pharmacology research field of drug discovery for the treatment of various ailments including cancer, gangrene, malaria, and HIV. She is experienced in experimental laboratory research, research involving the use of animals, and clinical research. Her research addresses challenges of chemoresistance and chemotoxicity through the discovery of new lead compounds, identification of proteins and genes responsible for drug resistance and treatment failure, and development of targeted of chemotherapeutic nano-delivery systems.